Downregulation of TMEM220 Promotes Tumor Progression in Hepatocellular Carcinoma

Ting Li, Lei Guan, Guangbo Tang, Bing He, Lili Huang, Juan Wang, Mingyue Li, Yanxia Bai, Xinyuan Li, Huqin Zhang

Abstract

Background: In the process of long-term carcinogenesis, cells accumulate many mutations. Deregulated genes expression causes profound changes in cell proliferation, which is one of the hallmarks of HCC. Comprehensive understanding of these changes will contribute to the molecular mechanism of HCC progression. Methods: Western blot and real-time PCR analyses were performed to examine the TMEM220 expression in HCC. Patients’ transcript profiling was used to identify gene cohorts related to TMEM220. Reverse phase protein arrays (RPPA) were preformed to obtain expression data for TMEM220 relevant proteins. The effect of TMEM220 on tumor growth and metastasis were analyzed by in vitro and in vivo studies. Results: Through clinical sample analysis, we found that TMEM220 is downregulated in tumor and lower levels of TMEM220 is associated with poor prognosis in HCC patients. Through overexpressing TMEM220 in HCC cell lines, we found that the proliferation of cancer cells was significantly slowed down and metastasis was significantly reduced. For further study of its molecular mechanism, we performed Reverse Phase Protein Array (RPPA). The results suggest that phenotypic changes caused by TMEM220 in HCC cells might be associated with FOXO and PI3K-Akt pathways. Mechanism studies showed that overexpression of TMEM220 could regulate β-catenin and FOXO3 transcriptional activity by altering their subcellular localization, affecting the expression of downstream gene p21 and SNAIL, and ultimately reducing the progression of HCC. Conclusion: Altogether, our study proposes a working model in which upregulation of TMEM220 expression alters the genes expression involved in cell proliferation, thereby inhibiting HCC progression, which suggests that TMEM220 might serve as a clinical biomarker.

Introduction

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies globally, particularly in Asia and Africa. Often diagnosed at advanced stages, many patients miss the window for surgical intervention, necessitating a deeper understanding of the molecular mechanisms driving tumor progression. Identifying the "molecular brakes" that normally regulate cell growth but fail during carcinogenesis is critical for developing new diagnostic and therapeutic strategies.

While the transmembrane protein (TMEM) family is known to play various roles in cell signaling, the specific function of TMEM220 in liver cancer has remained largely unexplored. This study aimed to characterize the role of TMEM220 in HCC progression and elucidate the molecular machinery through which it operates.

Materials and Methods

The researchers employed a multi-disciplinary approach to investigate TMEM220:

  • Clinical Validation: Analysis of 120 paired tumor and healthy liver samples from patients, supplemented by public genomic data from TCGA, Oncomine, and NCBI.
  • High-Throughput Proteomics: Reverse Phase Protein Array (RPPA) was used to screen 131 proteins to identify signaling pathways disrupted by TMEM220 overexpression.
  • Functional Assays: CRISPR-like overexpression models in HCC cell lines (SMMC7721, MHCC97H, and HCCLM3) were used to evaluate cell proliferation, migration, and invasion.
  • In Vivo Models: Xenograft and metastasis studies were conducted in nude mice to observe tumor growth and spread to the lungs and liver.
  • Localization Studies: Immunofluorescence and Chromatin Immunoprecipitation (ChIP) tracked the subcellular movement of transcription factors β-catenin and FOXO3.

Results

Clinical Significance and Expression Patterns

TMEM220 was found to be significantly downregulated in 91.7% of the clinical HCC samples analyzed. Data from public databases confirmed that TMEM220 expression is highest in normal liver and kidney tissues but drops sharply in cancerous states. Crucially, patients with high TMEM220 expression demonstrated significantly better 5-year survival rates compared to those with low expression, marking it as a potent prognostic biomarker.

Figure 1: TMEM220 expression patterns and clinical significance in HCC.

Inhibition of Tumor Growth and Metastasis

Functional assays revealed that overexpressing TMEM220 effectively slows the "engine" of tumor growth by causing a significant increase in cells arrested in the G1 phase. In mouse models, this translated to a dramatic reduction in the number of metastatic nodules in both the liver and the lungs, suggesting that TMEM220 acts as a dual-action brake on both proliferation and spread.

Molecular Mechanism: The Traffic Controller

RPPA data indicated that TMEM220 suppresses the PI3K-Akt pathway, reducing the phosphorylation of Akt and GSK3β. The study found that TMEM220 acts as a gatekeeper for protein localization:

  1. β-catenin Inhibition: TMEM220 forces β-catenin out of the nucleus, inhibiting the SNAIL axis and preventing the Epithelial-Mesenchymal Transition (EMT) required for metastasis.
  2. FOXO3 Activation: It ushers FOXO3 into the nucleus, increasing the expression of p21 to halt the cell cycle.

Discussion and Conclusion

The study establishes TMEM220 as a critical tumor suppressor in HCC. Beyond its role in the PI3K-Akt and FOXO3 pathways, the authors hypothesize that TMEM220 may inhibit the oncogenic c-MET pathway by regulating intracellular calcium levels, given its structural similarity to cation channels.

While the link between TMEM220 loss and tumor progression is clear, future work is needed to confirm its potential calcium channel activity and to identify the specific triggers for TMEM220 gene methylation and downregulation during early carcinogenesis. Ultimately, restoring TMEM220 function represents a promising avenue for future HCC therapies.

Summary updated

Abstract

<title>Abstract</title> <bold>Background:</bold> In the process of long-term carcinogenesis, cells accumulate many mutations. Deregulated genes expression causes profound changes in cell proliferation, which is one of the hallmarks of HCC. Comprehensive understanding of these changes will contribute to the molecular mechanism of HCC progression. <bold>Methods:</bold> Western blot and real-time PCR analyses were performed to examine the TMEM220 expression in HCC. Patients’ transcript profiling was used to identify gene cohorts related to TMEM220. Reverse phase protein arrays (RPPA) were preformed to obtain expression data for TMEM220 relevant proteins. The effect of TMEM220 on tumor growth and metastasis were analyzed by in vitro and in vivo studies.<bold>Results: </bold>Through clinical sample analysis, we found that TMEM220 is downregulated in tumor and lower levels of TMEM220 is associated with poor prognosis in HCC patients. Through overexpressing TMEM220 in HCC cell lines, we found that the proliferation of cancer cells was significantly slowed down and metastasis was significantly reduced. For further study of its molecular mechanism, we performed Reverse Phase Protein Array (RPPA). The results suggest that phenotypic changes caused by TMEM220 in HCC cells might be associated with FOXO and PI3K-Akt pathways. Mechanism studies showed that overexpression of TMEM220 could regulate β-catenin and FOXO3 transcriptional activity by altering their subcellular localization, affecting the expression of downstream gene p21 and SNAIL, and ultimately reducing the progression of HCC. <bold>Conclusion: </bold>Altogether, our study proposes a working model in which upregulation of TMEM220 expression alters the genes expression involved in cell proliferation, thereby inhibiting HCC progression, which suggests that TMEM220 might serve as a clinical biomarker.
BibTeX
@inproceedings{li2021downregulation,
  author = {Ting Li and Lei Guan and Guangbo Tang and Bing He and Lili Huang and Juan Wang and Mingyue Li and Yanxia Bai and Xinyuan Li and Huqin Zhang},
  title = {{Downregulation of TMEM220 Promotes Tumor Progression in Hepatocellular Carcinoma}},
  booktitle = {Research Square},
  year = {2021},
  doi = {10.21203/rs.3.rs-221265/v1},
}
Figure